Anesthesiology, Pain Medicine · Los Angeles, CA
NPI
1679511638
Since 2006
Specialty
Anesthesiology, Pain Medicine
Code 207LP2900X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
266 S Harvard Blvd, # 350
Los Angeles, CA, 90004
Phone (213) 444-6255
Groups this clinician bills Medicare through
Medicare paid, 2024
$184K
9,046 services
Medicare patients, 2024
144
Average age 80
Drug cost, 2024
$2.0M
2,251 prescriptions
Company payments, 2025
$1,856
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Philip S Doh was code 99213 (office e&m - established), 778 times for 128 patients. In total Philip S Doh billed 9,046 services in 30 codes, and Medicare paid $184K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-08-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 778 | 128 | $75.40 | $59K |
| J1885 Injection, ketorolac tromethamine, per 15 mg | Office | 663 | 60 | $0.52 | $344 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 647 | 75 | $0.78 | $508 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 200 | 13 | $0.09 | $18.25 |
| 20611 Joint Injection | Office | 183 | 29 | $85.52 | $16K |
| J7324 Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | Office | 173 | 25 | $98.35 | $17K |
| 96372 Injection Administration | Office | 145 | 53 | $12.29 | $1,781 |
| 76942 Ultrasound - Nonspecific | Office | 136 | 67 | $50.87 | $6,918 |
| 82962 Clinical Chemistry | Office | 108 | 34 | $3.21 | $347 |
| 20550 Musculoskeletal | Office | 91 | 27 | $25.69 | $2,338 |
| 20553 Musculoskeletal | Office | 81 | 46 | $27.90 | $2,260 |
| 64445 Nerve Block Injection - Back | Office | 71 | 45 | $137.70 | $9,776 |
| 99204 Office E&M - New | Office | 51 | 51 | $138.33 | $7,055 |
| 64418 Musculoskeletal | Office | 43 | 26 | $72.34 | $3,110 |
| 96360 Intravenous Infusion, Hydration | Office | 21 | 13 | $29.21 | $614 |
By year: 2022 $185K for 6,889 services; 2023 $236K for 10,166 services; 2024 $184K for 9,046 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 108 | 34 | $3.21 | $347 |
Medicare prescription drug claims, 2024
In 2024, the drug Philip S Doh prescribed most often to Medicare patients was Tramadol Hcl, with 567 prescriptions and refills. In total Philip S Doh wrote 2,251 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tramadol Hcl Generic | 567 | 568 | 199 | $1,248 |
| Licart Diclofenac Epolamine | 384 | 812 | 149 | $580K |
| Tymlos Abaloparatide | 236 | 236 | 51 | $618K |
| Gabapentin Generic | 185 | 197 | 79 | $1,702 |
| Prolia Denosumab | 127 | 762 | 75 | $216K |
| Pregabalin Generic | 124 | 134 | 40 | $2,240 |
| Horizant Gabapentin Enacarbil | 116 | 128 | 26 | $129K |
| Trulicity Dulaglutide | 65 | 65 | 11 | $62K |
| Easy Touch Alcohol Prep Pads Alcohol Antiseptic Pads | 40 | 45 | 20 | $89.67 |
| Buprenorphine Hcl Generic | 35 | 35 | Under 11 | $1,341 |
| Evenity (2 Syringes) Romosozumab-Aqqg | 34 | 34 | 19 | $82K |
| Duloxetine Hcl Generic | 27 | 32 | Under 11 | $285 |
| Diclofenac Epolamine Generic | 24 | 24 | Under 11 | $11K |
| Belbuca Buprenorphine Hcl | 23 | 23 | Under 11 | $16K |
| Relistor Methylnaltrexone Bromide | 21 | 39 | 13 | $94K |
Brand drugs: 1,119 claims; generic drugs: 1,039 claims; opioid claims: 611.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Philip S Doh $1,856 ($1,856 in general payments such as food, travel and fees) from 6 companies. The largest payer was Amgen Inc. with $1,011.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.